Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / LLY - ALX Oncology gastric cancer candidate wins orphan drug status from EC

LLY - ALX Oncology gastric cancer candidate wins orphan drug status from EC

Eli Lilly and Company

2023-06-26 09:38:25 ET

  • The European Commission has awarded orphan drug status to ALX Oncology's ( NASDAQ: ALXO ) evorpacept for gastric cancer.
  • The classification covers both gastric cancer and gastroesophageal junction adenocarcinoma.
  • The US FDA granted orphan drug status for the candidate for the gastric cancer indication in January 2022.
  • ALX ( ALXO ) plans to release data in H2 of this year from ASPEN-06, a phase 2 trial of evorpacept in combination with trastuzumab, paclitaxel and Eli Lilly ( LLY ) Cyramza (ramucirumab) for the  HER2-positive gastric cancer.
  • Seeking Alpha's Quant Rating views ALX Oncology ( ALXO ) as a hold.

For further details see:

ALX Oncology gastric cancer candidate wins orphan drug status from EC
Stock Information
Company Name: Eli Lilly and Company
Stock Symbol: LLY
Market: NYSE
Website: lilly.com
Menu
LLY LLY Quote LLY Short LLY News LLY Articles LLY Message Board
Get LLY Alerts

News, Short Squeeze, Breakout and More Instantly...